Tag: prostate specific antigen (PSA)

1. In this cohort study, a novel prognostic model was developed to estimate prostate cancer-specific mortality (PCSM) while accounting for ...

1. A retrospective analysis demonstrated that prostate-specific antigen (PSA) screening has overall declined in popularity in recent years. 2. Health ...

1. 5-year progression-free status was greatest in group 3 (triple therapy) and lowest in group 1 (pelvic bed radiotherapy alone). ...

1. Abiraterone acetate plus standard treatment significantly increased length of metastasis-free survival in men with non-metastatic prostate cancer compared to ...

1. Ipatasertib-abiraterone treatment significantly improved progression-free survival compared to placebo-abiraterone in patients with PTEN-loss metastatic castration-resistant prostate cancer. 2. Grade ...

1. 3-year event-free survival rates were significantly greater in the 18F-fluciclovine-PET group compared to conventional imaging. 2. Adverse reactions and ...

1. Radiolabeled Lutetium-177 offered greater PSA response versus current standard of care, cabazitaxel. 2. Fewer grade 3-4 adverse events occurred ...

1. Relugolix was shown to significantly decrease testosterone levels for a sustained period of time in male patients with advanced ...

There is a need for focal therapies for low to intermediate-risk prostate cancers, as whole-gland therapies have many complications without ...